At the personal invitation of Yan Yiyi, the chairman of the board of directors, on the afternoon of September 19, Ding Jian, academician of the Chinese Academy of Engineering, Zhang Haiyan, researcher of the Chinese Academy of Sciences Shanghai Institute of Materia Medica, Huang Chenggang and a delegation of three people visited the Zhejiang headquarters of Chengyi Pharmaceutical to give special technical guidance to the company's "research and innovation projects".
▲Academician Ding Jian and his delegation watched the company's promotional video.
Dongtou in September has a clear and crisp autumn weather. At around 2 pm, Chairman Yan Yiyi personally lined up with all the executives and relevant department personnel in the company to welcome Academician Ding Jian and his delegation. At the special technical guidance meeting, Chairman Yan Yiyi delivered a speech stating that the epidemic has not yet ended. Academician Ding and his team have made several adjustments and arrangements, squeezed out time in strict epidemic control, and have been servants all the way to Cheng Yi Pharmaceutical, demonstrating their deep friendship for Cheng Yi Pharmaceutical and the spirit of scientific exploration for new drug research and innovation.
Cheng Yi Pharmaceutical is researching and creating the "nervonic acid" project, which carries out the development and research of APIs and preparations while applying for and registering health products. The research institute of the company has increased the purity of the drug substance from 85% to 99%. At present, the trial produced "Nerve Acid Soft Capsule" has achieved 99% of the purity of nervonic acid and 99% of the purity of DHA, achieving preliminary results.
▲Academician Ding Jian.
▲Researcher Zhang Haiyan.
▲Researcher Huang Chenggang.
Yan Yiyi, Ren Bingjun, Yi Zhibiao, and Lv Zhidong respectively introduced the company's work in this project. At present, it is a critical period for Chengyi Pharmaceutical to make significant strides from the "generic drug stage" to the "innovative drug stage". This is a pioneering move that involves various challenges and opportunities. Therefore, three scientists from the Shanghai Institute of Pharmacy, Chinese Academy of Sciences, are invited to come and provide guidance.
At the special technical guidance meeting on the afternoon of September 19th, Academician Ding Jian, Researcher Zhang Haiyan, and Researcher Huang Chenggang listened to the report and consulted relevant materials to analyze and study the company's research and innovation work. They then spoke separately and put forward many valuable opinions and suggestions, clarifying the company's thinking and pointing out the direction.
▲Chairman Yan Yiyi held the "Nerve Acid Soft Capsule" product successfully trial produced by the company.
Academician Ding Jian said that on his second visit to Dongtou, he saw significant changes in Cheng Yi pharmaceutical industry. Since the outbreak of the epidemic, many domestic enterprises have been greatly impacted, but Cheng Yi Pharmaceutical has been moving upwards, indicating that the products are excellent, the market is rigid, and the prospects will be very bright.
On the morning of September 20th, scientists Ding Jian, Huang Chenggang, and Zhang Haiyan once again came to Cheng Yi Pharmaceutical to suggest collecting effective evidence on how to avoid detours in the company's "research and innovation projects"; Improve the work that should be completed first; And conducted in-depth discussions and guidance on the "technical roadmap" deployed by the company.